Omnicell Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Omnicell de 94.4% y 3.6% respectivamente, mientras que el BPA crecerá en un 99.2% al año.

Información clave

103.8%

Tasa de crecimiento de los beneficios

107.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.7%
Tasa de crecimiento de los ingresos	3.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	31 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

May 25

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Mar 28

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 29

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Nov 10

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Sep 06

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Aug 08

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Jul 02

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Jun 08

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Apr 29

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Apr 11

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Mar 23

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Feb 28

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

Jan 15

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Jan 01

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Nov 17

Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Nov 03

Omnicell launches Specialty Pharmacy Services

Oct 11

Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Sep 30

Omnicell says advance services to drive profitable growth in long-run: Investor Day

Sep 20

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Sep 15

Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Aug 31

Omnicell reports Q2 earnings miss; reaffirms FY22 guidance and issues Q3 outlook

Aug 04

Are Investors Undervaluing Omnicell, Inc. (NASDAQ:OMCL) By 41%?

Aug 03

Omnicell Fails To Justify Inclusion In Long-Only, Equity-Focused Portfolio

Jul 21

We Ran A Stock Scan For Earnings Growth And Omnicell (NASDAQ:OMCL) Passed With Ease

Jun 27

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Jun 13

Omnicell's (NASDAQ:OMCL) Returns On Capital Are Heading Higher

May 30

These 4 Measures Indicate That Omnicell (NASDAQ:OMCL) Is Using Debt Safely

May 05

With EPS Growth And More, Omnicell (NASDAQ:OMCL) Is Interesting

Mar 16

What Is Omnicell, Inc.'s (NASDAQ:OMCL) Share Price Doing?

Mar 04

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:OMCL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,165	-5	64	N/A	2
12/31/2025	1,136	18	41	118	8
12/31/2024	1,070	-12	12	122	8
3/31/2024	1,103	-21	165	218	N/A
12/31/2023	1,147	-20	126	181	N/A
9/30/2023	1,186	-34	165	225	N/A
6/30/2023	1,235	-23	127	189	N/A
3/31/2023	1,268	-18	48	107	N/A
12/31/2022	1,296	6	17	78	N/A
9/30/2022	1,309	48	-5	55	N/A
6/30/2022	1,258	61	18	77	N/A
3/31/2022	1,199	72	98	158	N/A
12/31/2021	1,132	78	173	232	N/A
9/30/2021	1,070	80	195	249	N/A
6/30/2021	987	60	194	242	N/A
3/31/2021	914	35	164	218	N/A
12/31/2020	892	32	131	186	N/A
9/30/2020	891	38	86	144	N/A
6/30/2020	906	49	101	164	N/A
3/31/2020	924	69	85	144	N/A
12/31/2019	897	61	83	145	N/A
9/30/2019	860	54	98	158	N/A
6/30/2019	836	48	59	117	N/A
3/31/2019	807	38	55	112	N/A
12/31/2018	787	38	50	104	N/A
9/30/2018	772	54	8	61	N/A
6/30/2018	754	48	-19	27	N/A
3/31/2018	747	44	-23	16	N/A
12/31/2017	713	31	N/A	25	N/A
9/30/2017	688	-1	N/A	45	N/A
6/30/2017	678	-6	N/A	72	N/A
3/31/2017	670	-9	N/A	56	N/A
12/31/2016	696	10	N/A	50	N/A
9/30/2016	651	8	N/A	54	N/A
6/30/2016	599	14	N/A	40	N/A
3/31/2016	539	24	N/A	44	N/A
12/31/2015	485	31	N/A	38	N/A
9/30/2015	476	32	N/A	37	N/A
6/30/2015	463	32	N/A	50	N/A
3/31/2015	455	31	N/A	75	N/A
12/31/2014	441	31	N/A	65	N/A
9/30/2014	425	28	N/A	49	N/A
6/30/2014	407	29	N/A	59	N/A
3/31/2014	395	27	N/A	52	N/A
12/31/2013	381	24	N/A	55	N/A
9/30/2013	365	23	N/A	53	N/A
6/30/2013	355	22	N/A	42	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que OMCL sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que OMCL sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que OMCL sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2.1% al año) de OMCL crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.1% al año) de OMCL crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OMCL se prevé que sea elevada dentro de 3 años.

Omnicell Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 732%

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Price target decreased by 28% to US$44.50

Price target decreased by 7.7% to US$64.14

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Recent updates

Now 20% undervalued

Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Omnicell, Inc. Announces XT Amplify

Omnicell, Inc. to Report Q1, 2024 Results on May 02, 2024

Omnicell, Inc., Annual General Meeting, May 21, 2024

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

New minor risk - Shareholder dilution

High number of new directors

Omnicell, Inc. Announces Executive Changes

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell Is Building A Strong Moat

Consensus EPS estimates fall by 732%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Omnicell, Inc. Reports Unaudited Impairment Changes Results for the Fourth Quarter Ended December 31, 2023

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024

Omnicell, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Omnicell, Inc. Announces Board Changes

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Price target decreased by 28% to US$44.50

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 7.7% to US$64.14

Omnicell, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Omnicell, Inc. Announces Board Changes

Now 20% undervalued after recent price drop

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

New minor risk - Shareholder dilution

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Omnicell, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Omnicell, Inc. Appoints Bobby Ghoshal to Board of Directors

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Founder recently bought US$295k worth of stock

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Omnicell Announces Leadership and Organizational Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Lead Independent Director exercised options and sold US$377k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Consensus EPS estimates fall by 19%

Omnicell, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Omnicell, Inc. to Showcase Advanced Services Designed to Deliver Enhanced Medication Management Outcomes at ASHP Midyear 2022

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Price target decreased to US$84.44

Price target decreased to US$123

Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Omnicell, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Omnicell launches Specialty Pharmacy Services

Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Price target decreased to US$147

Omnicell says advance services to drive profitable growth in long-run: Investor Day

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?